News & Events
News & Events
Institut Pasteur Korea, in collaboration with the Global Antibiotic R&D Partnership (GARDP), discovered new antibiotic candidates active against drug-resistant bacteria
2024-04-05
Institut Pasteur Korea, in collaboration with
the Global Antibiotic R&D Partnership (GARDP), discovered
new antibiotic candidates active against drug-resistant bacteria
the Global Antibiotic R&D Partnership (GARDP), discovered
new antibiotic candidates active against drug-resistant bacteria
Institut Pasteur Korea (IPK), in collaboration with the Global Antibiotic R&D Partnership (GARDP), has identified new molecules active against drug-resistant bacteria. The study was published in EBioMedicine, a prestigious international biomedical journal.
▶ Clink here to read full article
.png)
The Antibiotic Resistance Lab and Screening Discovery Platform at IPK have been collaborating with GARDP since 2018 with the aim of discovering new antibiotics that effectively inhibit Klebsiella pneumoniae and Acinetobacter baumannii.
The researchers designed an assay to evaluate the antibacterial efficacy in cell culture experiments and conducted high-content/high-throughput screening.
By evaluating the efficacy of more than 48,000 compounds provided by global pharmaceutical companies such as Takeda Pharmaceutical, Daiichi Sankyo Pharmaceutical, and Eisai Pharmaceutical, 72 compounds were confirmed with activity against K. pneumoniae and drug-resistant A. baumannii, with two showing activity against extensively drug-resistant (XDR) A. baumannii.
Institut Pasteur Korea began research collaborating with GARDP in 2018, signed a memorandum understanding in 2023, and is working to develop new treatments to respond to antibiotic resistance, referred to as the 'silent pandemic', through cooperation with global organizations.